Physician profile
Sy Rabins
NPI 1013965649
$3,091.30
in general payments reported to CMS, 2019-2025
28 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $271 · 2021: $104 · 2022: $848 · 2023: $101 · 2024: $246 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $401.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $374.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $270.28 | 2019-2025 | |
| Novo Nordisk INC | $269.09 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $192.05 | 2019-2022 | |
| Lilly USA, LLC | $178.55 | 2019-2025 | Mounjaro, Zepbound |
| Silk Road Medical, INC. | $165.21 | 2022 | |
| Exact Sciences Corporation | $140.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $139.13 | 2019-2022 | |
| Centinel Spine, LLC | $133.26 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $126.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $125.50 | 2020 | |
| Astellas Pharma US INC | $109.24 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $63.35 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $60.85 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.74 | 2019-2020 | |
| Abbott Laboratories | $57.23 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $38.72 | 2025 | |
| Phathom Pharmaceuticals, INC. | $29.05 | 2024-2025 | Voquezna |
| Abbvie INC. | $28.96 | 2024 | |
| Globus Medical, INC. | $22.71 | 2025 | Senza |
| Amarin Pharma, INC. | $20.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.33 | 2025 | Onpattro |
| Amag Pharmaceuticals, INC. | $13.29 | 2019 | |
| Therapeuticsmd, INC. | $12.93 | 2019 | |
| Allergan, INC. | $12.52 | 2019 | |
| Zyla Life Sciences, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sy Rabins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.